[Proceedings: Clinical experience with administration of 2 alpha, 3 alpha- epithio-5 alpha-androstan-17 beta- yl, 1-methoxy-cyclopentyl ether (10364-S) in breast diseases].
D045930:Anabolic Agents / Q000627:therapeutic use; D000731:Androstanes / Q000627:therapeutic use*; D001941:Breast Diseases / Q000188:drug therapy*; D004987:Ethers / Q000627:therapeutic use; D005260:Female; D006801:Humans; D013440:Sulfides / Q000627:therapeutic use
D045930:Anabolic Agents; D000731:Androstanes; D004987:Ethers; D013440:Sulfides